TW202348248A - 液體製劑及其製備方法與用途 - Google Patents

液體製劑及其製備方法與用途 Download PDF

Info

Publication number
TW202348248A
TW202348248A TW112105172A TW112105172A TW202348248A TW 202348248 A TW202348248 A TW 202348248A TW 112105172 A TW112105172 A TW 112105172A TW 112105172 A TW112105172 A TW 112105172A TW 202348248 A TW202348248 A TW 202348248A
Authority
TW
Taiwan
Prior art keywords
chelating agent
liquid
serum albumin
human serum
botulinum toxin
Prior art date
Application number
TW112105172A
Other languages
English (en)
Chinese (zh)
Inventor
卡爾海因茨 艾斯勒
克勞斯 芬克
哈羅德Ｖ 泰勒
克勞迪婭 捷凱
卡佳 庫巴赫
Original Assignee
德商梅茲製藥有限兩合公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 德商梅茲製藥有限兩合公司 filed Critical 德商梅茲製藥有限兩合公司
Publication of TW202348248A publication Critical patent/TW202348248A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A61K38/385—Serum albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Birds (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
TW112105172A 2022-02-15 2023-02-14 液體製劑及其製備方法與用途 TW202348248A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP22156843 2022-02-15
EP22156843.9 2022-02-15
EP22183172 2022-07-05
EP22183172.0 2022-07-05

Publications (1)

Publication Number Publication Date
TW202348248A true TW202348248A (zh) 2023-12-16

Family

ID=85202119

Family Applications (1)

Application Number Title Priority Date Filing Date
TW112105172A TW202348248A (zh) 2022-02-15 2023-02-14 液體製劑及其製備方法與用途

Country Status (13)

Country Link
US (1) US20250152682A1 (https=)
EP (1) EP4479023A1 (https=)
JP (1) JP2025504249A (https=)
KR (1) KR20240141340A (https=)
CN (1) CN119031902A (https=)
AR (1) AR128514A1 (https=)
AU (1) AU2023221507A1 (https=)
CA (1) CA3243238A1 (https=)
CO (1) CO2024010940A2 (https=)
IL (1) IL315004A (https=)
MX (1) MX2024009970A (https=)
TW (1) TW202348248A (https=)
WO (1) WO2023156389A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025228877A1 (en) 2024-04-29 2025-11-06 Merz Therapeutics GmbH Botulinum toxin for the preventive treatment of migraine
WO2026021713A1 (en) 2024-07-23 2026-01-29 Merz Therapeutics GmbH Uses of magnetic nerve stimulation associated with botulinum neurotoxin administration

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7780967B2 (en) * 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
US20060269575A1 (en) * 2000-02-08 2006-11-30 Allergan, Inc. Botulinum toxin pharmaceutical compositions formulated with recombinant albumin
JP2006045173A (ja) * 2004-08-09 2006-02-16 Hidetoshi Tsuchida 表面修飾血清アルブミン−金属ポルフィリン複合体、およびそれを含有する酸素輸液
PT2271670E (pt) 2008-03-14 2014-11-28 Allergan Inc Ensaio imunobaseado da atividade do serotipo a da toxina botulínica
CA2766649C (en) * 2009-06-24 2016-08-23 Charles N.S. Soparkar Zinc supplementation to increase responsiveness to metalloprotease therapy
ES2653249T3 (es) 2011-09-29 2018-02-06 Cellsnap, Llc Composiciones y métodos para ensayos de toxigenicidad
AU2014301116B2 (en) 2013-06-28 2019-11-14 Merz Pharma Gmbh & Co. Kgaa Means and methods for the determination of the biological activity of Neurotoxin polypeptides in cells
PL3463432T3 (pl) * 2016-05-27 2021-04-19 Ipsen Biopharm Limited Ciekła formulacja neurotoksyny stabilizowana tryptofanem lub tyrozyną

Also Published As

Publication number Publication date
MX2024009970A (es) 2024-09-18
US20250152682A1 (en) 2025-05-15
AR128514A1 (es) 2024-05-15
KR20240141340A (ko) 2024-09-26
CN119031902A (zh) 2024-11-26
JP2025504249A (ja) 2025-02-06
WO2023156389A1 (en) 2023-08-24
CA3243238A1 (en) 2023-08-24
EP4479023A1 (en) 2024-12-25
IL315004A (en) 2024-10-01
CO2024010940A2 (es) 2024-09-19
AU2023221507A1 (en) 2024-08-08

Similar Documents

Publication Publication Date Title
JP2021193103A (ja) ボツリヌス神経毒素を得るためのプロセスおよびシステム
KR101997615B1 (ko) 보툴리눔 독소 및 안정화제를 포함하는 액상 제형 및 이의 제조방법
CA2532475C (en) Formulation for a protein pharmaceutical without added human serum albumin (hsa)
TW202348248A (zh) 液體製劑及其製備方法與用途
JPS6214271B2 (https=)
TW202400223A (zh) 液體製劑及其製備方法與用途
WO2010016895A1 (en) Compositions of activated botulinum toxin type b
CA1066621A (en) Dialdehyde treatment of tetanus toxin and derivative obtained
HK40113170A (zh) 液体肉毒杆菌毒素制剂及其用途
US9358294B2 (en) Method for formulating a vaccine containing at least two antigens capable of adsorbing onto aluminium oxyhydroxide
ES2993230A2 (es) Composiciones de la neurotoxina de Clostridium botulinum serotipo A
CN114146054B (zh) 一种醋酸奥曲肽注射液的制备工艺
CN121693325A (zh) 液体肉毒杆菌毒素制剂及其用途
KR20260052068A (ko) 보툴리눔 독소 액체 제형 및 그 용도
HK40116988A (zh) 液体肉毒杆菌毒素制剂及其用途
US20100034854A1 (en) Compositions of activated botulinum holotoxin type B (150 KD)
CN118126144B (zh) 一种a型重组肉毒素的纯化方法
WO2010051038A1 (en) Compositions of activated botulinum holotoxin type b (150 kd)
ES2992717A2 (es) Variantes de la secuencia de la neurotoxina de Clostridium botulinum serotipo A (BoNT/A)